A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Completed · Phase 2 · Has a placebo group
Conditions studied: Open-angle Glaucoma, Ocular Hypertension
In brief
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field loss. This study is being conducted to determine how well DE-126 ophthalmic solution works (efficacy) in safely lowering IOP when dosed as topical eyedrops. This study will evaluate the safety and efficacy of four (4) concentrations of DE-126, when compared with latanoprost (0.005%) eye drops in patients with primary open-angle glaucoma or ocular hypertension. The IOP will be measured at 3 different times throughout the day, over 6 total visits during a 3-month treatment period (with up to 4 extra weeks observation if the patient must stop taking current eye drops to lower IOP). Safety assessments will be done throughout the study, including ocular signs and symptoms, vital signs, and clinical laboratory tests. While the most important time-point to measure IOP in this study and evaluate efficacy will be at the final study visit (month 3), IOP values will also be evaluated at other visits throughout the 3-month treatment period.
Key facts
- Study ID
- NCT03216902
- Run by
- Santen Inc.
- People needed
- 241
- Starts
- 2017-07-25
- Expected to finish
- 2018-02-27
- Last updated by the study team
- 2020-10-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Provide signed written informed consent
- Diagnosis of POAG or OHT in both eyes
- Qualifying corrected visual acuity in each eye
- Qualifying central corneal thickness in each eye
- Qualifying Day 1 IOP measurement at 3 time-points in both eyes
- Qualifying Anterior chamber angle
You may not qualify if…
- History of ocular surgery specifically intended to lower IOP
- Subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period
- Advanced glaucoma in either eye
- Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry
- Any ocular surgery or ocular laser treatment within 90 days prior to Visit 1 (Screening) and throughout the study in either eye
- Females who are pregnant, nursing, or planning a pregnancy
Where it is running
- Sall Research Medical Center, Inc — Artesia, California, United States
- North Valley Eye Medical Group — Mission Hills, California, United States
- Eye Research Foundation, INC — Newport Beach, California, United States
- North Bay Eye Associates, Inc. — Petaluma, California, United States
- Shettle Eye Research, Inc. — Largo, Florida, United States
- Clayton Eye Clinical Research, LLC — Morrow, Georgia, United States
- Coastal Research Associates, LLC — Roswell, Georgia, United States
- Rochester Ophthalmological Group, PC — Rochester, New York, United States
- Mundorf Eye Center — Charlotte, North Carolina, United States
- Cornerstone Health Care, LLC — High Point, North Carolina, United States
- Keystone Research Ltd SMO/Texan Eye, PA — Austin, Texas, United States
- Keystone Research LTD SMO/Medical Center Ophthalmology Assoc. — San Antonio, Texas, United States
- Murakami Karindoh Hospital — Fukuoka-shi, Fukuoka, Japan
- Nagasaka Eye Clinic — Nagoya-shi, Aichi, Japan
- Sugiura Eye Clinic — Osaka-shi, Osaka, Japan
- Sapporo Katoh Ophthalmology Clinic — Sapporo-shi, Hokkaido, Japan
- Dogenzaka Kato Eye Clinic — Shibuya-ku, Tokyo, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.